Literature DB >> 8998173

Harnessing the power of antisense technology for combination chemotherapy.

R Narayanan.   

Abstract

Mesh:

Substances:

Year:  1997        PMID: 8998173     DOI: 10.1093/jnci/89.2.107

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells.

Authors:  Jian-Hui Yang; Yi-Chu Zhang; Hui-Qing Qian
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.